Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Lung Neoplasms 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Advanced Malignancies 2Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × tanespimycin × Clear all
NCT01193491 2015-04-15

Dose Escalation of IPI-493 in Hematologic Malignancies

Infinity Pharmaceuticals, Inc.

Phase 1 Terminated
4 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00113204 2008-05-20

IPi-504-01

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡